Loading
Life sciences · Journal article
Acs Omega · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Targeting redox homeostasis represents a promising strategy to overcome adaptive mechanisms that sustain cancer cell survival under therapeutic stress. Here, we evaluated a pharmacological sensitization strategy based on quercetin (Q) preconditioning followed by treatment with 3′,5′-dimaleamylbenzoic acid (DMAB), aimed at exploiting glutathione-dependent vulnerabilities in cervical cancer cells. Q and DMAB exhibited synergistic interactions across a 6 × 6 concentration matrix, with a marked leftward shift in the dose–response profile within the IC50-proximal range. Combined treatment was associated with significant depletion of intracellular glutathione (GSH) and a reduction in the GSH/GSSG ratio, consistent with disruption of redox buffering capacity. Functionally, Q + DMAB reduced HeLa cell viability to 23% at 48 h and markedly increased apoptotic cell death (75%), accompanied by S-phase cell cycle arrest and inhibition of cell migration. Notably, cytotoxic effects were attenuated in nonmalignant epithelial cells. In vivo, combined administration significantly reduced tumor burden (69%) and improved survival in a murine L5178-Y lymphoma model, without overt signs of systemic toxicity. Collectively, these results demonstrate that Q enhances the antitumor activity of DMAB through modulation of glutathione-dependent redox homeostasis and support the potential of redox-directed combination strategies in cancer therapy.